Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 19/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411001 | 0.91 | CAPN1 (0.51) | CAPN1CTSLCTSBCTSSCTSK | |
| SCHEMBL30133673 | 0.87 | CAPN1 (0.59) | CAPN1CTSLCTSB | |
| SCHEMBL20028395 | 0.87 | CAPN1 (0.59) | CAPN1CTSLCTSB | |
| SCHEMBL22885962 | 0.86 | CAPN1 (0.52) | CAPN1CTSLCTSBCTSSCTSK | |
| Dazcapistat SCHEMBL21854271 | 0.85 | CAPN1 (0.53) | CAPN1CTSLCTSBCTSS | |
| Dazcapistat SCHEMBL20027782 | 0.85 | CAPN1 (0.53) | CAPN1CTSLCTSBCTSS | |
| Dazcapistat SCHEMBL21854319 | 0.85 | CAPN1 (0.53) | CAPN1CTSLCTSBCTSS | |
| SCHEMBL22885961 | 0.85 | CAPN1 (0.51) | CAPN1CTSLCTSB | |
| SCHEMBL21411422 | 0.85 | CAPN1 (0.57) | CAPN1CTSLCTSB | |
| SCHEMBL22886638 | 0.85 | PYGL (0.43) | CAPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-3774737-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Blade Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
| CN-112204014-A | Calpain modulators and therapeutic uses thereof | 布莱德治疗公司 | 2021-01-08 | — | — | CN | disclosed |
| WO-2019190885-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885CTSL 54/4885CTSB 24/4885 |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSL 257/4885CTSB 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.